Inflectra (Infliximab) Wholesaler

Inflectra (Infliximab)   Distributor, wholesaler

INFLECTA (INFLIXIMAB) DESCRIPTION:

Inflectra is an anti-inflammatory medicine that contains the active substance infliximab. The active substance in Inflectra, infliximab, is a monoclonal antibody. A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and attach to a specific structure (called an antigen) in the body. Infliximab has been designed to attach to a chemical messenger in the body called tumour necrosis factor-alpha (TNF-alpha). This messenger is involved in causing inflammation and is found at high levels in patients with the diseases that Inflectra is used to treat. By blocking TNF-alpha, infliximab improves the inflammation and other symptoms of the diseases. Inflectra is produced by a method known as ‘recombinant DNA technology’. The infliximab is made by cells that have received a gene (DNA), which makes them able to produce it. 

Inflexra is the first FDA-apporved biosimilar for Remicade (Infliximab).

INFLECTA (INFLIXIMAB) INDICATIONS: 

• Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease (CD) who have had an inadequate response to conventional therapy
• Reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD

• Reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy

• Reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy

• Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis, in combination with methotrexate

• Reducing signs and symptoms in patients with active ankylosing spondylitis

• Reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with psoriatic arthritis

• Treatment of adult patients with chronic severe (ie, extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate
• INFLECTRA^® should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician

DOSAGE FORM & STRENGTH:

• Inflectra (infliximab) 100mg Distributor , WHOLESALE

Rasso swiss pharma is a Inflectra (infliximab) distributor, wholesaler, supplier.

<< Back to products